Doctors Note Logo

Published on: 9/12/2026

Can Voltaren gel cause a heart attack or stomach bleeding like oral NSAIDs?

Topical diclofenac (Voltaren gel) carries the same FDA boxed warnings for cardiovascular events and gastrointestinal bleeding as oral NSAIDs, but far less of the drug reaches your bloodstream, so the actual risk is considerably lower for most people. Serious stomach bleeding, ulcers, heart attack, and stroke remain possible, particularly with large application areas, long-term daily use, existing heart or kidney disease, blood thinners, or combining the gel with oral NSAIDs like ibuprofen. Warning signs that need urgent attention include black or bloody stools, vomiting blood, chest pain, sudden weakness on one side, or slurred speech. There are several important factors that determine your personal risk, including dosing limits and drug interactions, so see below to understand more.

If you are weighing whether your pain relief plan is safe or you have noticed symptoms that worry you, a few minutes of clarity can make your next step much easier. A free, instant, online symptom check asks the same kinds of questions a clinician would, then helps you understand what may be going on and whether you should self-monitor, book a visit, or seek care right away.

Last reviewed for medical accuracy: 09/12/2026

answer background

Explanation

Can Voltaren gel cause a heart attack or stomach bleeding like oral NSAIDs?

Voltaren gel is a topical formulation of diclofenac, a non-steroidal anti-inflammatory drug (NSAID). Unlike oral NSAIDs, which circulate widely through the body, Voltaren gel is applied directly to the skin over joints or muscles. This targeted delivery reduces—but does not entirely eliminate—the chance of systemic side effects such as heart problems or gastrointestinal bleeding. Below is a balanced look at what you need to know.

How Voltaren gel works
Voltaren gel (diclofenac 1% topical gel) relieves pain and inflammation by inhibiting cyclooxygenase enzymes (COX-1 and COX-2) right where you apply it.
• Localized delivery means much lower blood levels of diclofenac compared to an oral pill.
• Peak blood concentrations are about 6% of those seen with an equivalent oral dose.
• The gel is intended for use on joints like knees, elbows or shoulders, or on soft-tissue injuries.

Systemic absorption and risks
Because Voltaren gel does get absorbed through skin, there is a small potential for systemic adverse effects. Key points:
• Average systemic absorption ranges from 5%–17% of the applied dose, depending on the area of application, amount used and skin condition.
• In healthy adults using recommended amounts, blood levels remain far below those with oral diclofenac.
• However, if you apply the gel over large areas, under occlusion (e.g., covered by a bandage), or use it at high doses for prolonged periods, systemic exposure can increase.

Heart attack and cardiovascular risk
Oral NSAIDs carry a boxed warning for increased risk of heart attack, stroke and serious cardiovascular events—especially with higher doses and long-term use. For Voltaren gel:
• Clinical trials and post-marketing data have shown no clear link between standard topical use and a significant increase in heart attack or stroke.
• Because systemic absorption is low, the risk appears much smaller than with oral NSAIDs.
• Nonetheless, the U.S. prescribing information advises caution in patients with existing cardiovascular disease, hypertension or risk factors such as smoking, high cholesterol or diabetes.
• If you have had a heart attack, stroke or heart failure, talk to your doctor before using any NSAID, including Voltaren gel.

Stomach bleeding and gastrointestinal safety
Oral NSAIDs can irritate the stomach lining, leading to ulcers, bleeding and perforation. With Voltaren gel:
• Local application greatly reduces direct contact with the gastrointestinal (GI) tract.
• Reports of stomach ulcers or bleeding linked directly to topical diclofenac are extremely rare.
• In studies comparing topical versus oral diclofenac, topical users had substantially fewer GI complaints.
• Still, if enough drug enters the bloodstream, theoretical GI risks remain—especially in people with a history of ulcers or on blood thinners.

Who may still be at risk
Even with topical use, certain individuals should use Voltaren gel with care or avoid it entirely:
• People with active or past gastrointestinal ulcers, bleeding or perforation.
• Those with known cardiovascular disease, uncontrolled hypertension or risk factors for stroke.
• Patients on anticoagulants (blood thinners) or corticosteroids, which can magnify bleeding risk.
• Individuals with kidney impairment—NSAIDs can reduce blood flow to the kidneys.
• Elderly patients, who may absorb more drug through thinner skin and are more susceptible to side effects.

Safe use tips
To minimize risk when using Voltaren gel:
• Apply exactly as directed—typically 2–4 grams (one or two “fingers” of gel) to the affected area, 3–4 times per day.
• Do not cover with airtight dressings unless your doctor advises it.
• Wash your hands after application (unless you’re treating your hands).
• Avoid applying to broken or irritated skin.
• Limit the treated area to no more than 320 cm2 per joint (about the size of your hand plus fingers).
• Do not exceed 32 grams of gel per day over all affected areas.
• Use the lowest effective dose for the shortest duration needed to control symptoms.

Monitoring for side effects
Even though the risks are lower, stay alert for any new or worsening symptoms. Seek medical advice if you experience:
• Chest pain, shortness of breath, weakness on one side of the body, slurred speech or vision changes (signs of cardiovascular events).
• Severe stomach pain, black or tar-colored stools, or vomiting blood (signs of GI bleeding).
• Swelling, weight gain or difficulty breathing (signs of heart failure).
• Decreased urine output, swelling in the legs or confusion (potential kidney issues).
• Unexplained rash, itching, or signs of an allergic reaction.

When to seek help
If you ever suspect a serious side effect, do not wait. Contact emergency services or go to the nearest emergency department. For less urgent concerns, you can do a free, online symptom check, using the doctor approved Ubie Symptom Checker.

Balancing benefits and risks
Voltaren gel offers pain relief with fewer systemic side effects compared to oral NSAIDs. Most users tolerate it well when used appropriately. Still, no medication is entirely risk-free. Discuss your personal health history with a healthcare provider before starting Voltaren gel—especially if you have cardiovascular or gastrointestinal concerns.

Key takeaways
• Voltaren gel delivers diclofenac locally, with much lower blood levels than oral forms.
• The risk of heart attack, stroke and stomach bleeding is significantly less but not zero.
• Follow dosing instructions carefully and avoid using over large areas or under bandages unless directed.
• Monitor for any warning signs of cardiovascular or GI problems.
• Consider your personal risk factors—age, medical history and concurrent medications—before use.

Speak to a doctor
Always talk with a qualified healthcare professional before starting or stopping any medication. If you have symptoms that could be life-threatening or serious, seek immediate medical attention.

(References)

  • * Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30. PMID: 23726390; PMCID: PMC3778977.

  • * Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM, Egger M, Jüni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011 Jan 11;342:c7086. doi: 10.1136/bmj.c7086. Epub 2011 Jan 11. PMID: 21224324; PMCID: PMC3019238.

  • * Fischbach W. [Drug-induced gastrointestinal bleeding]. Internist (Berl). 2019 Jun;60(6):597-607. doi: 10.1007/s00108-019-0610-y. PMID: 31076795.

  • * Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F, Sturkenboom M, Perez-Gutthann S, Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi: 10.2165/11633470-000000000-00000. PMID: 23137151; PMCID: PMC3714137.

  • * Chang CH, Kao CC. Hemophagocytic lymphohistiocytosis and myopericarditis induced by campylobacter: a case report. BMC Infect Dis. 2024 Apr 8;24(1):382. doi: 10.1186/s12879-024-09128-z. Epub 2024 Apr 8. PMID: 38589812; PMCID: PMC11003181.

  • * Garner SE, Fidan DD, Frankish R, Maxwell L. Rofecoxib for osteoarthritis. Cochrane Database Syst Rev. 2005 Jan 25;2005(1):CD005115. doi: 10.1002/14651858.CD005115. Epub 2005 Jan 25. PMID: 15654705; PMCID: PMC8864971.

  • * Cinar H, Yanmaz LE, Ozmen O, Ozbeyli A, Bektas B. Effects of Topical Steroids and Non-Steroidal Anti-Inflammatory Drugs on Gastrointestinal Bleeding in Rats. Vet Med Sci. 2026 May;12(3):e70962. doi: 10.1002/vms3.70962. PMID: 42030432; PMCID: PMC13108708.

  • * Dalal D, Dubreuil M, Peloquin C, Neogi T, Zhang Y, Choi H, Felson D. Meloxicam and risk of myocardial infarction: a population-based nested case-control study. Rheumatol Int. 2017 Dec;37(12):2071-2078. doi: 10.1007/s00296-017-3835-x. Epub 2017 Oct 13. PMID: 29030657; PMCID: PMC8143590.

  • * Pemberton RE, Strand LJ. A review of upper-gastrointestinal effects of the newer nonsteroidal antiinflammatory agents. Dig Dis Sci. 1979 Jan;24(1):53-64. doi: 10.1007/BF01297239. PMID: 371938.

  • * Bally M, Beauchamp ME, Abrahamowicz M, Nadeau L, Brophy JM. Risk of acute myocardial infarction with real-world NSAIDs depends on dose and timing of exposure. Pharmacoepidemiol Drug Saf. 2018 Jan;27(1):69-77. doi: 10.1002/pds.4358. Epub 2017 Nov 24. PMID: 29171096.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.